TEVA PHARMACEUTICAL INDUSTRIES Business Summary

Teva Pharmaceutical Industries Ltd. (TEVA) operates a diversified biopharmaceutical business model, generating revenue through the development, manufacturing, and marketing of generic medicines, specialty (innovative) therapeutics, and biosimilars. The company's revenue streams are primarily derived from high-volume generic product sales, licensing agreements, and milestone payments, such as its strategic collaboration with Sanofi. As of early 2026, Teva has restructured its reporting into four primary segments: United States, Europe, International Markets, and Other Activities, the latter of which now includes its Anda distribution business to sharpen the firm's focus on its "Pivot to Growth" biopharmaceutical strategy. Teva maintains a dominant global position as a leading producer of generic drugs while aggressively expanding its innovative portfolio, led by flagship brands Austedo, Ajovy, and Uzedy. It competes directly with generic giants Sandoz and Viatris, as well as specialty-focused peers like GSK and Sanofi, positioning itself as a hybrid leader transitioning from a legacy generics powerhouse to an innovation-driven biopharma entity. Leadership is currently spearheaded by President and CEO Richard Francis, who joined in 2023 with a high-pedigree background including five years as CEO of Sandoz and executive roles at Biogen. The executive team includes Eliyahu Kalif as EVP and Chief Financial Officer and Dr. Eric Hughes as EVP of Global R&D and Chief Medical Officer. The company's governance is overseen by Independent Chairman Dr. Sol J. Barer, a veteran pharmaceutical executive and former Chairman of Celgene. Teva traces its origins to the 1901 founding of Salomon, Levin, and Elstein Ltd. and the 1935 incorporation of Teva Pharmaceutical & Chemical Works by Günther Friedländer and Else Kober. Notable institutional influence is exerted by major shareholders including Vanguard, BlackRock, and activist investor Elliott Investment Management, which secured board representation in 2025 to oversee the company’s strategic deleveraging and margin expansion targets.